Literature DB >> 17671224

Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.

Chun-Peng Liao1, Chen Zhong, Gohar Saribekyan, James Bading, Ryan Park, Peter S Conti, Rex Moats, Anton Berns, Wei Shi, Zongxiang Zhou, Alexander Yu Nikitin, Pradip Roy-Burman.   

Abstract

The application of Cre/loxP technology has resulted in a new generation of conditional mouse models of prostate cancer. Here, we describe the improvement of the conditional Pten deletion model of prostate adenocarcinoma by combining it with either a conditional luciferase or enhanced green fluorescent protein reporter line. In these models, the recombination mechanism that inactivates the Pten alleles also activates the reporter gene. In the luciferase reporter model, the growth of the primary cancer can be followed noninvasively by bioluminescence imaging (BLI). Surgical castration of tumor-bearing animals leads to a reduced bioluminescence signal corresponding to tumor regression that is verified at necropsy. When castrated animals are maintained, the emergence of androgen depletion-independent cancer is detected using BLI at times varying from 7 to 28 weeks postcastration. The ability to monitor growth, regression, or relapse of the tumor with the use of BLI lead to the collection of tumors at different stages of development. By comparing the distribution of phenotypically distinct populations of epithelial cells in cancer tissues, we noted that the degree of hyperplasia of cells with neuroendocrine differentiation significantly increases in the recurrent cancer relative to the primary cancer, a characteristic which may parallel the appearance of a neuroendocrine phenotype in human androgen depletion-independent cancer. The enhanced green fluorescent protein model, at necropsy, can provide an opportunity to locate or assess tumor volume or to isolate enriched populations of cancer cells from tumor tissues via fluorescence-based technologies. These refined models should be useful in the elucidation of mechanisms of prostate cancer progression, and for the development of approaches to preclinical intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671224     DOI: 10.1158/0008-5472.CAN-07-0668

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  In vivo optical imaging and dynamic contrast methods for biomedical research.

Authors:  Elizabeth M C Hillman; Cyrus B Amoozegar; Tracy Wang; Addason F H McCaslin; Matthew B Bouchard; James Mansfield; Richard M Levenson
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

Review 2.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.

Authors:  Helty Adisetiyo; Mengmeng Liang; Chun-Peng Liao; Joseph H Jeong; Michael B Cohen; Pradip Roy-Burman; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2014-09       Impact factor: 6.384

4.  Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy.

Authors:  Rong Zhong; Matt Pytynia; Charles Pelizzari; Michael Spiotto
Journal:  Cancer Res       Date:  2014-02-13       Impact factor: 12.701

5.  Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis.

Authors:  Ren Liu; Xiuqing Li; Wenming Gao; Yue Zhou; Shiuan Wey; Satyajit K Mitra; Valery Krasnoperov; Dezheng Dong; Shuanglong Liu; Dan Li; Genyuan Zhu; Stan Louie; Peter S Conti; Zibo Li; Amy S Lee; Parkash S Gill
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

6.  Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Authors:  Linda Kim Pham; Mengmeng Liang; Helty A Adisetiyo; Chun-Peng Liao; Michael B Cohen; Stanley M Tahara; Baruch Frenkel; Noriyuki Kasahara; Pradip Roy-Burman
Journal:  Endocr Relat Cancer       Date:  2013-11-04       Impact factor: 5.678

Review 7.  Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo.

Authors:  Brandon Kocher; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2013-04-12       Impact factor: 39.397

8.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

9.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

10.  CAF-secreted annexin A1 induces prostate cancer cells to gain stem cell-like features.

Authors:  Lauren A Geary; Kevin A Nash; Helty Adisetiyo; Mengmeng Liang; Chun-Peng Liao; Joseph H Jeong; Ebrahim Zandi; Pradip Roy-Burman
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.